Scholarlink

<p>MASLD is now the prevailing disease worldwide. This disease is influenced by genetic predisposition. TLRs play a vital role in the pathogenesis of MASLD.</p><p><b>Aim of the work</b> Investigate toll like receptor gene 7 and gene 9 in MASLD. Patients and methods: This is a cross-sectional Study that will be conducted on 207 participants attending to tropical medicine department, faculty of medicine at Helwan University over a period of about 12 months.</p><p><b>Inclusion criteria </b>(1) Participants aged 18 years or older, of both sexes. (2) Patients diagnosed with MASLD by ultrasound and FibroScan. </p><p><b>Exclusion criteria </b>(1) Alcohol drinkers. (2) Patients with autoimmune liver disease, viral hepatitis, or chronic liver disease. The participants were divided into two groups: an intervention group of (100) participants with MASLD and a control group of (107) participants without MASLD.</p><p><b>Results </b>Regarding Toll-like receptor 7, F0-F1 patients had higher levels of TLR7 than healthy controls (1.2±0.84 vs. 0.92±0.22) respectively (<i>p</i>1=0.002). Moreover, F2-F3 patients had higher levels of TLR7 than healthy controls (1.4±1.1 vs. 0.92±0.22), respectively (<i>p</i>2=0.004). However, there was no statistically significant difference between F1-F2 patients and F2-F3 patients regarding TLR7 serum level (1.2±0.84 vs. 1.4±1.1; respectively) (<i>p</i>3=0.368). Regarding Toll-like receptor 9, there was no statistically significant difference between healthy controls and F0-F1 (0.93±0.25 vs. 0.82±0.34; <i>p</i>1=0.124). However, the mRNA serum level of TLR9 was higher in F2-F3 patients than in healthy controls with a statistically significant difference (1.8±0.74 vs. 0.93±0.25, respectively; <i>p</i>2=0.001) and higher in F2-F3 than in F0-F1 patients (1.8±0.74 vs. 0.82±0.34, respectively; <i>p</i>3=0.001). There was a significant positive correlation between TLR9 and CAP score (<i>r</i>= 0.804, <i>p</i>= 0.001).</p><p><b>Conclusion </b>TLR7 and TLR9 expression levels were associated with MASLD and fibrosis stage, but the cross-sectional design does not allow conclusions about disease progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Toll-like receptor gene 7 and gene 9 in MASLD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Amal Ahmed,
  • Marwa Tahoon,
  • Lamees Ahmed Samy,
  • May Selim,
  • Sofia Ashraf,
  • Amira Yones,
  • Wafaa Abdelhamid,
  • Reem A. Abdelghafour,
  • Randa Ibrahim,
  • Ahmed Ramadan Mohamed,
  • Mohamed El-Kassas,
  • Reem Ezzat Mahdy

摘要

MASLD is now the prevailing disease worldwide. This disease is influenced by genetic predisposition. TLRs play a vital role in the pathogenesis of MASLD.

Aim of the work Investigate toll like receptor gene 7 and gene 9 in MASLD. Patients and methods: This is a cross-sectional Study that will be conducted on 207 participants attending to tropical medicine department, faculty of medicine at Helwan University over a period of about 12 months.

Inclusion criteria (1) Participants aged 18 years or older, of both sexes. (2) Patients diagnosed with MASLD by ultrasound and FibroScan.

Exclusion criteria (1) Alcohol drinkers. (2) Patients with autoimmune liver disease, viral hepatitis, or chronic liver disease. The participants were divided into two groups: an intervention group of (100) participants with MASLD and a control group of (107) participants without MASLD.

Results Regarding Toll-like receptor 7, F0-F1 patients had higher levels of TLR7 than healthy controls (1.2±0.84 vs. 0.92±0.22) respectively (p1=0.002). Moreover, F2-F3 patients had higher levels of TLR7 than healthy controls (1.4±1.1 vs. 0.92±0.22), respectively (p2=0.004). However, there was no statistically significant difference between F1-F2 patients and F2-F3 patients regarding TLR7 serum level (1.2±0.84 vs. 1.4±1.1; respectively) (p3=0.368). Regarding Toll-like receptor 9, there was no statistically significant difference between healthy controls and F0-F1 (0.93±0.25 vs. 0.82±0.34; p1=0.124). However, the mRNA serum level of TLR9 was higher in F2-F3 patients than in healthy controls with a statistically significant difference (1.8±0.74 vs. 0.93±0.25, respectively; p2=0.001) and higher in F2-F3 than in F0-F1 patients (1.8±0.74 vs. 0.82±0.34, respectively; p3=0.001). There was a significant positive correlation between TLR9 and CAP score (r= 0.804, p= 0.001).

Conclusion TLR7 and TLR9 expression levels were associated with MASLD and fibrosis stage, but the cross-sectional design does not allow conclusions about disease progression.